There are limited reports about the investigation of
A. baumannii in the hospital environment from Iran and other countries of the region (
13-
16). We screened surfaces and equipment of five hospitals and observed a high frequency (53.1%) of CRAB isolates which were simultaneously resistant to some tested antimicrobial agents. Previously, the high distribution of XDR
A. baumannii in clinical isolates was reported in hospitals of Tehran, central Iran (
7,
17). Based on the present results, tigecycline exhibited promising
in vitro activity against
A. baumannii isolates. This finding is in agreement with previous works, showing the highest susceptibility of
A. baumannii clinical isolates to tigecyclin (
18). Therefore, this antibiotic might be regarded as a treatment option for infections due to MDR/XDR
A. baumannii (
19,
20).
CRAB isolates were also detected on devices often used for patient care such as portable X-ray and also on surfaces touched by staff and patients.
A. baumannii might first spread from infected patients or colonized personnel/visitors and then contaminate surfaces, thereby acting as prolonged sources for HAIs. Several studies suggested that
A. baumannii could colonize different medical equipment and surfaces (
11,
21,
22) and also could persist for years in patients (
23) with the ability of biofilm formation (
11). In the present study, we observed a significant MDR (21.9%) and XDR (18.8%) frequency. The XDR rate in this study was lower than the usual reported rates of clinical
A. baumannii isolates, as it reached more than 90% in one report from Tehran (
7). However, the MDR rate in this study was higher than reported rates of clinical isolates.
The ERIC-PCR result revealed at least four distinct clusters of
A. baumannii in ICUs of all the hospitals except for H2 which showed two STs. In this study, some
A. baumannii isolates with similar typing pattern were recovered from the different hospitals, indicating that clonal expansion of certain strains might take place in some of the hospitals probably through shared visitors or patients. Despite the clonal relatedness of these strains, the presence of the
blaOXA-23 gene was not demonstrated for these isolates, and the resistance profiles of 127 - 1 and 383 - 1 were not identical. This discrepancy might be explained to some extent by the potential of
A. baumannii to acquire foreign resistance elements as a result of selective pressure forced with antibiotics in patients and/or with antiseptics in the healthcare environment (
24,
25).
A notable issue is the detection of two isolates in one clone from two geographically distinct hospitals, which were both obtained from ventilator. This suggests the possible potential of some specific genotypes of
A. baumannii to resist and overcome hospital conditions, leading to inter-hospital dissemination of the same clones. Ventilator associated pneumonia due to MDR
A. baumannii is one of the most common nosocomial infections, which accounts for high mortality rate in ICU hospitalized patients (
26).
Detection of three different clones from baby bath sink of the H1 NICU and three different clones from bed sheet of the H4 ICU, which were all recovered in the same month, may reflect a heavy contamination source of endogenous
A. baumannii and probably failure to conform to control measures and guidelines in these hospitals (
27).
In different regions of Iran, OXA type β-lactamases have been widely studied in clinical isolates of
A. baumannii (
17,
28,
29) and it has been shown that
blaOXA-23 is the most frequent OTC gene among nosocomial
A. baumannii isolates (
17,
30-
33). However, data on the distribution of
blaOXA-23 in the environmental isolates of
A. baumannii is uncommon. While in this study, 31.3% of the isolates had
blaOXA-23, a recent study from Iran reported that 77.5% of 40 strains isolated from air, water and surfaces carried
blaOXA-23 (
34). Similarly, other studies suggested higher frequency of 68.7% (
15), 58% (
20) and 43.3% (
27) for
blaOXA-23 gene positive isolates in the hospital environment, as compared to the present results. The stability and circulation of
blaOXA-23 producing isolates may finally result in acquisition and horizontal transferring of genes to other strains.
We detected one
blaOXA-58 positive isolate. The first known
blaOXA-58 producing
Acinetobacter isolate was recovered in France in 2003. The co-occurrence of
blaOXA-23 and
blaOXA-58 in clinical isolates has been reported occasionally (
30,
35-
38). There is evidence supporting the presence of
blaOXA-58 carbapenemase in outbreak strains of
A. baumannii and its contribution in CRAB outbreaks occurring in hospitals (
38-
41).
5.1. Conclusions
This study provides evidence of the presence of clonally related blaOXA-23 producing CRAB in the hospital environment, particularly on moist surfaces in ICUs of tertiary hospitals. The clinical significance of multi resistant A. baumannii is of great concern since the distribution of the same clones in different hospitals on equipment such as ventilator may increase the risk of cross-colonization of vulnerable patients. Moreover, a combination of multi-drug resistance and blaOXA-23 and/or blaOXA-58 may result in sustained surveillance of such isolates in the healthcare environment and their involvement in outbreaks.